Shelter Mutual Insurance Co Purchases Shares of 32,110 Gilead Sciences, Inc. $GILD

Shelter Mutual Insurance Co bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 32,110 shares of the biopharmaceutical company’s stock, valued at approximately $4,057,000.

Several other hedge funds have also bought and sold shares of the stock. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences in the fourth quarter worth $25,000. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC raised its position in shares of Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares in the last quarter. Quattro Advisors LLC bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $26,000. Finally, Wealth Preservation Advisors LLC grew its position in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the sale, the director owned 10,066 shares in the company, valued at $1,459,771.32. This represents a 33.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the transaction, the chief financial officer directly owned 165,646 shares of the company’s stock, valued at $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 87,000 shares of company stock valued at $11,562,960 over the last three months. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Up 1.9%

NASDAQ:GILD opened at $146.12 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The firm has a market cap of $181.18 billion, a PE ratio of -54.73 and a beta of 0.32. The company has a 50-day moving average of $131.97 and a 200 day moving average of $136.59. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same quarter in the previous year, the business posted $2.01 EPS. Gilead Sciences’s revenue was up 10.6% on a year-over-year basis. As a group, research analysts anticipate that Gilead Sciences, Inc. will post -0.51 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s payout ratio is presently -122.85%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on GILD shares. Morgan Stanley decreased their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research report on Monday, July 27th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 20th. Needham & Company LLC restated a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Barclays lowered their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. Twenty-four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.